Roche Unveils Promising Data for SMA and DMD at MDA 2025

At the 2025 Muscular Dystrophy Association (MDA) conference in Dallas, Roche shared compelling new data from its neuromuscular portfolio, reinforcing the impact of its treatments for spinal muscular atrophy (SMA) and Duchenne muscular dystrophy (DMD). The five-year findings from the SUNFISH study show that patients with Types 2 and 3 SMA who received Evrysdi experienced long-term stabilization in motor function, a crucial milestone for those facing progressive muscle weakness. Caregivers also reported improvements in daily independence, underscoring the treatment’s real-world benefits.

Alongside these results, Roche presented promising updates on Elevidys, the first gene therapy for DMD, showing potential to slow disease progression. Dr. Levi Garraway, Roche’s Chief Medical Officer, emphasized the significance of these advancements, noting that they offer hope for individuals managing these complex conditions. With a high adherence rate and a strong safety profile, Evrysdi continues to provide a meaningful option for SMA patients, demonstrating its potential to improve quality of life over the long term.